Pediatric low-grade gliomas (pLGGs) represent a distinct subset of central nervous system tumors in children, characterized by unique biological features and therapeutic considerations that markedly differ from adult gliomas. Recent consensus guidelines emerging from China have synthesized multidisciplinary expertise, contemporary evidence, and clinical pragmatism to establish a comprehensive framework addressing the diagnosis and management of pLGGs. These meticulously developed recommendations underscore the significance of integrating advanced molecular diagnostics and tailoring treatment strategies to the specific developmental needs of pediatric patients, aiming to achieve optimal tumor control while safeguarding neurocognitive function and overall development.
Imaging plays a pivotal role in the initial evaluation and longitudinal monitoring of pLGGs. Magnetic resonance imaging (MRI), with its superior soft-tissue contrast resolution, remains indispensable. The typical neuroimaging signature of pLGGs includes hypointensity on T1-weighted imaging (T1WI) alongside hyperintense signals on T2-weighted and FLAIR sequences, indicative of the tumor’s intrinsic water content and structural characteristics. Notably, while peritumoral edema is often minimal or absent, certain histologic variants—such as pilocytic astrocytomas—exhibit pronounced contrast enhancement, reflecting their vascular profile and blood-brain barrier permeability. The consensus advises routine acquisition of conventional sequences supplemented by advanced modalities like diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), susceptibility-weighted imaging (SWI), magnetic resonance spectroscopy (MRS), and perfusion-weighted imaging (PWI) wherever feasible, to deepen diagnostic insights and guide therapeutic planning.
Postoperative and follow-up imaging protocols are pivotal for assessing residual tumor burden and detecting disease progression. The guidelines recommend obtaining an early postoperative MRI within 72 hours, or alternatively between two to three weeks if imaging is obscured by surgical artifacts. Sustained surveillance with three-month intervals is advocated to monitor for changes indicative of recurrence or progression. For radiologic response assessment, the RAPNO (Response Assessment in Pediatric Neuro-Oncology) 2020 criteria provide a standardized framework: an increase of at least 25% in the solid tumor component signals progression in non-cystic lesions, whereas in cystic tumors, progression is defined by solid growth or enhancement of the cyst wall, necessitating meticulous interpretation to differentiate true cystic degeneration from mixed lesion components.
The pathological diagnosis of pLGGs now transcends traditional histomorphological evaluation, incorporating sophisticated molecular characterization given the tumors’ predominant reliance on aberrations in the RAS/MAPK signaling pathway. Entities such as MYB or MYBL1-altered diffuse astrocytomas, angiocentric gliomas, polymorphous low-grade neuroepithelial tumors of youth, and diffuse low-grade gliomas with MAPK pathway alterations exemplify this molecular heterogeneity. Integrative histological and immunohistochemical analyses are mandatory across cases, supplemented by comprehensive molecular profiling and, when conventional methods yield equivocal results, DNA methylation assays to refine classification. The use of standardized diagnostic nomenclature aligning with the CNS WHO grading system further fortifies diagnostic accuracy and inter-institutional consistency.
Surgical intervention remains the cornerstone of pLGG management, with gross total resection (GTR) correlating strongly with prolonged progression-free survival and overall survival rates exceeding 90% over a decade. Nonetheless, the anatomical predilection of some tumors for eloquent or deep brain regions—such as the optic pathways, brainstem, and midline structures—complicates surgical strategy. In such scenarios, goal-oriented approaches prioritize maximal safe debulking, symptomatic relief, and procurement of diagnostic tissue through limited resection or biopsy. Emerging techniques, including laser interstitial thermal therapy, offer potential avenues for treating tumors inaccessible via traditional neurosurgical methods, although evidence supporting their widespread adoption remains preliminary.
Radiotherapy represents a double-edged sword in the treatment paradigm of pLGGs; while effective, it harbors the risk of severe long-term sequelae including cognitive deficits, endocrine dysregulation, cerebrovascular pathology, and secondary malignancies, particularly in very young children. Consequently, the guidelines advocate deferral or avoidance of radiation in children under three years, favoring chemotherapy or molecularly targeted therapies as frontline modalities. Radiotherapy is reserved for cases exhibiting progression post multiple therapeutic attempts or for symptomatic residual disease in children over three. Advanced techniques like intensity-modulated radiotherapy (IMRT) and proton therapy are preferred to optimally conform doses, minimizing exposure of healthy tissue. Precise immobilization and sedation protocols for uncooperative pediatric patients further enhance treatment fidelity and safety.
Systemic therapy holds a crucial position, especially when surgical excision is incomplete or when disease progression occurs. Among infants and toddlers, immediate chemotherapy initiation is imperative following incomplete resection, acknowledging their heightened vulnerability and limited tolerance for observation alone. For children over the age of three, chemotherapy is warranted in the setting of partial resection coupled with clinical or radiographic progression. Conventional regimens such as carboplatin and vincristine (CV) or the combination of thioguanine, procarbazine, lomustine, and vincristine (TPCV) achieve objective responses in approximately half of patients, with the caveat that TPCV is contraindicated for patients with neurofibromatosis type 1 due to secondary malignancy risks. Vinblastine monotherapy presents as a less intensive alternative with modest efficacy.
The advent of molecular-targeted therapies marks a paradigm shift in pLGG treatment, driven by the elucidation of key oncogenic drivers within the RAS/MAPK pathway. Precision pharmacologic agents now selectively inhibit aberrant molecular alterations: BRAF V600E mutations respond favorably to combined BRAF and MEK inhibition via dabrafenib and trametinib, agents approved by regulatory authorities for pediatric use. Contrastingly, BRAF fusion-positive tumors are refractory to first-generation BRAF inhibitors, necessitating alternatives such as MEK inhibitors or second-generation compounds like tovorafenib. Targeting of mTOR signaling with everolimus is effective in subependymal giant cell astrocytomas associated with TSC1/2 mutations, while NTRK fusion-mediated tumors benefit from TRK inhibitors like larotrectinib and entrectinib. These targeted interventions have been incorporated as high-strength recommendations, reflecting robust evidence for their efficacy and safety profiles.
Despite advancements, about half of pLGG patients ultimately experience relapse or disease progression following initial therapy, underscoring the need for individualized salvage strategies. Molecular profiling continues to guide therapeutic choices in this setting, with re-administration of prior chemotherapies, second-line agents such as temozolomide, and biologics like bevacizumab employed depending on clinical context. Targeted agents tailored to specific genetic alterations are strongly favored when applicable. Comprehensive management of relapsed pLGGs demands balancing tumor control with minimization of cumulative toxicities, warranting prospective randomized trials to establish standardized protocols in the salvage setting.
Collectively, the Chinese national consensus guidelines crystallize a diligent, evidence-based approach to the nuanced care of pediatric low-grade gliomas, emphasizing the fusion of multidisciplinary expertise, molecular insights, and age-appropriate treatment algorithms. The guidelines highlight critical priorities: deployment of multimodal imaging and molecular diagnostics to enable precise classification and targeted therapy, judicious use of radiotherapy to curtail long-term morbidity, and utilization of cutting-edge surgical and systemic modalities. Nonetheless, gaps remain, particularly regarding the validation of novel local therapies and optimization of salvage chemotherapy regimens. Future directions hinge on the conduct of molecularly informed randomized controlled trials and the development of preclinical models that faithfully recapitulate pediatric glioma biology.
In an era progressively defined by precision oncology, these guidelines not only enhance standardized clinical care in China but also contribute substantially to the global neurosurgical and neuro-oncological communities. They underscore the imperative of balancing aggressive tumor control against the preservation of neurodevelopmental integrity, charting a path toward improved survival and quality of life in children afflicted with these complex tumors. With ongoing research and international collaboration, the horizon for managing pediatric low-grade gliomas promises continued evolution toward ever more effective and less toxic therapies.
Subject of Research: Pediatric low-grade gliomas; molecular diagnostics; multimodal imaging; surgical and systemic therapy strategies.
Article Title: Guidelines for the Diagnosis and Treatment of Pediatric Low-Grade Gliomas in China (2024)
News Publication Date: March 28, 2026
Web References:
https://www.xiahepublishing.com/journals/nsss
http://dx.doi.org/10.14218/NSSS.2026.00004
Keywords: Pediatric low-grade gliomas, neuro-oncology, RAS/MAPK pathway, molecular targeted therapy, MRI, neurosurgery, radiotherapy, chemotherapy, BRAF mutation, precision medicine.
Tags: 2024 pediatric glioma consensus guidelinesadvanced MRI techniques for brain tumorsdiffusion-weighted imaging in gliomasmolecular diagnostics in pediatric gliomasMRI imaging for pediatric gliomasmultidisciplinary approach to pediatric gliomasneurocognitive preservation in pediatric tumorsneuroimaging features of low-grade gliomaspediatric brain tumor treatment guidelinespediatric CNS tumor management Chinapediatric low-grade gliomas diagnosispilocytic astrocytoma imaging characteristics
